35.30 0.00 (0.00%)
After hours: 4:57PM EST
|Bid||35.01 x 1200|
|Ask||36.25 x 800|
|Day's Range||34.68 - 36.47|
|52 Week Range||19.06 - 53.70|
|Beta (3Y Monthly)||3.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.13|
Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10. That day, the stock price closed at $20.89, which is a ~63% fall from its 52-week high of $56.70 on December 21, 2017. The stock price fell from $48.68 at the close of the market on December 29, 2017, to $20.89 on December 10, 2018, reflecting a ~57% YTD (year-to-date) fall. Portola Pharmaceuticals hit a 52-week low of $18.18 on November 7.
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Novocure (NVCR) announced today that the results of a retrospective post-hoc sub-group analysis of its EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) have been published in the Journal of Neuro-Oncology. The analysis demonstrated that more time on Optune predicted increased survival in patients who received Optune plus temozolomide compared to patients who received temozolomide alone. Optune is a noninvasive, portable medical device that delivers Tumor Treating Fields to people with GBM.
Novocure (NVCR) announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit in Shanghai, China. The award is part of the BayHelix China Healthcare Awards series, celebrating outstanding individuals and companies for their achievement and contribution to China’s health care ecosystem. Novocure, a global oncology company developing Tumor Treating Fields – a proprietary platform technology for the treatment of solid tumors – and Zai Lab, a Shanghai-based innovative biopharmaceutical company, announced in September an exclusive license agreement for Tumor Treating Fields, including the brand name Optune®, for use in oncology in Greater China and a global strategic development collaboration.
Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, and Novocure Limited (NVCR) today announced that they have received the Deal of the Year Award at the 9th Annual BayHelix Awards Lunch Banquet held during the annual BioCentury-BayHelix China Healthcare Summit in Shanghai, China. The annual award recognizes a groundbreaking collaboration, technology transfer, licensing, capital raising, M&A or joint venture that involves a Chinese company in the healthcare sector. In September of this year, Zai Lab and Novocure announced a strategic collaboration and an exclusive license agreement in the field of oncology by which Zai lab would develop and launch Novocure’s Tumor Treating Fields (TTFields) technology, under the brand name Optune®, in Greater China and to collaborate with Novocure in the global development of the product. TTFields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.
Presentations span 21 research areas with five oral presentations
Novocure announced today that it will host an investor event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle, Novocure’s Executive Chairman, Dr. Samantha Du, Zai Lab’s CEO, and Tao Fu, Zai Lab’s President and Chief Operating Officer, will review the strategic collaboration for Tumor Treating Fields in Greater China and address questions from the audience.
NovoCure Limited’s (NASDAQ:NVCR): NovoCure Limited engages in the development, manufacture, and commercialization of Tumor Treating Fields for the treatment of solid tumors. The US$2.9b market-cap company’s loss lessens since it Read More...
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NovoCure (NVCR) delivered earnings and revenue surprises of 13.33% and -1.30%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018
Professor Palti invented Tumor Treating Fields and founded Novocure in 2000. “We have been honored to work so closely with Professor Palti for the last 18 years,” said Novocure CEO Asaf Danziger.
Post-hoc analysis of EF-14 phase 3 pivotal trial demonstrated that power loss density and electric field intensity were associated with improved overall survival, independent of co
The Tumor Treating Fields plus gemcitabine and nab-paclitaxel patient cohort showed progression free and one-year survivals that were more than double those of the gemcitabine and
Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.” The mean rating for NovoCure is 1.6 with a target price of $56.50. That implies an upside potential of 24.4% over its trading price of $45.42 on October 18.
NovoCure’s (NVCR) gross income is expected to rise 28.22% to $44.82 million in the third quarter of 2018. Its gross margin is expected to contract from 69.76% in the third quarter of fiscal 2017 to 68.7% in the third quarter of fiscal 2018. NovoCure’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 67.97% and 72.72%, respectively.
NovoCure (NVCR) is expected to report its third quarter of fiscal 2018 earnings on October 25. NovoCure’s clinical programs are evaluating the use of tumor-treating fields in various indications, including brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and liver cancer. Analysts expect NovoCure’s revenues to increase 30.47%, from $50.11 million in the third quarter of fiscal 2017 to $65.38 million in the third quarter of fiscal 2018.
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novocure (NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed GBM. Per Centers for Medicare & Medicaid Services (CMS) and Medicare policy, the two DME MACs will issue a single joint policy applicable in all DME regions.